Outset Medical Inc. (OM) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, OM scores 41 out of 100 with a letter grade of D- and a verdict of "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 8 / 20. The rating cites ROIC of -28% and an FCF yield of 0%. For an investor, this means the business is not currently converting capital into returns or distributable cash flow, so the investment case rests on future improvement rather than present earnings power.
• Whale 13F Flow: 10 / 20. The rating reflects institutional accumulation and options positioning. The source does not itemize holders, so the strength of this signal cannot be verified here.
• Insider Conviction: 5 / 20. The rating reflects SEC Form 4 and Congressional PTR cluster flow. This is the lowest-scoring pillar relative to its weight, suggesting limited insider confidence signals in the source data.
• Macro Regime Fit: 10 / 20. The rating cites a Beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level volatility, while the sector-sensitivity component is not further quantified in the source.
• Forensic Balance Sheet: 8 / 20. The rating cites an Altman Z-Score of 2.5, a Piotroski F-Score of 6/9, and Debt/Equity of 0.76. These are mid-range readings: the Z-Score and F-Score are not in the distress or strength extremes, but the balance sheet is not a source of strength for the thesis.

Taken together, the pillars point to a weak present-day cash engine offset partly by a moderate balance sheet and modest flow signals. A prospective investor would weigh upside drivers (any operational turnaround, recovery in margins, or institutional accumulation) against the valuation tradeoff of a stock whose price has fallen sharply from its 52-week high, with the rating's verdict indicating vulnerability in both flow and balance sheet. This is an analytical framing, not personalized advice.

Per the SEC financials, the company reported operating losses in each listed period, with the operating margin at -55.8% and net margin at -60% in the market data. Gross margin is 39.1%. ROIC is -28% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5, the Piotroski F-Score is 6/9, and Debt/Equity is 0.76. Cash declined from $124.0M to $35.0M across the two most recent periods shown, while debt declined from $197.4M to $96.2M.

Per the recent news and catalysts feed, the items are:

• An announcement of participation in the 2026 Stifel Healthcare Conference (YELLOW, market wire).
• A Q2 2026 earnings call transcript (YELLOW, market wire).
• A third-party commentary piece on DaVita stock (YELLOW, market wire), which is not specific to OM.
• An announcement that OM will report Q3 2026 results on November 4 (YELLOW, market wire). This is the nearest scheduled catalyst in the feed.
• A third-party commentary piece on Hims & Hers stock (YELLOW, market wire), which is not specific to OM.
• A third-party commentary piece on RXO stock (GREEN, catalyst), which is not specific to OM.

Per the Butterfly Supply-Chain Graph, no supply chain is mapped, no butterfly links are present, and no proprietary signals are recorded. Risk watch items drawn from the data are the pending Q3 2026 results and the cash decline noted above.

• What drives the negative operating margin, and what is the company's path to positive operating income?
• Why are forward P/E, EV/EBITDA, and EPS unavailable, and what is the current valuation on earnings-based metrics?
• What are the terms, maturities, and covenants of the $96.2M in debt relative to the $35.0M in cash?
• Which institutional holders and insiders are driving the whale and insider pillar scores, and what are their position sizes?
• What product, customer, and revenue-mix detail underlies the $119.5M in FY 2025 revenue?